Brief: Zai Lab Unveils Promising Phase 1 Data for DLL3 ADC; Launches Global Phase 3 Trial
Oct 24 (Reuters) - Zai Lab Ltd 9688.HK: ZAI LAB ANNOUNCES UPDATED PHASE 1 DATA FOR ZOCILURTATUG PELITECAN (FORMERLY ZL-1310), DEMONSTRATING POTENTIAL AS A FIRST-IN-CLASS/BEST-IN-CLASS DLL3-TARGETED ADC FOR SMALL CELL LUNG CANCER, AND INITIATION OF GLOBAL PHASE 3 REGISTRATIONAL STUDY ZAI LAB LTD - GLOBAL PHASE 3 TRIAL INITIATED FOR SECOND-LINE SCLC ZAI LAB LTD: FIRST-LINE SCLC & NEUROENDOCRINE CARCINOMA PROGRAMS ADVANCING TOWARD REGISTRATIONAL PHASE IN 2026 Source text: ID:nBw3sDtg1a Further company coverage: 9688.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows